BioSpace News Archive

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2020 on March 10, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it will report fourth quarter and full-year 2019 financial results and provide a business update on Thursday, March 12, 2020.

Cytokinetics, Incorporated (Nasdaq:CYTK) reported financial results for the fourth quarter and full year 2019

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three months and year ended December 31, 2019.

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and year-end 2019 financial results on March 16, 2020, after the market close

Exact Sciences Corp. announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two privately held companies based in Phoenix.

AVITA Medical, a global regenerative medicine company, announced that management will attend the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from Wednesday, March 18, 2020 through Thursday, March 19, 2020 at The Cliff Lodge in Snowbird, Utah.

Fourth Quarter Highlighted by Presentation of Positive DUR-928 Phase 2a Alcoholic Hepatitis Data at the Liver Meeting® 2019

Fiscal Year 2020 Total Revenues of $1,104.1M, up 28% Year-over-year; Q4 Total Revenues of $311.5M, up 34% Year-over-year

Enrollment Completion for MARIO-275, Infinity’s Global, Randomized Phase 2 Study in Patients with Urothelial Cancer, Expected in 2020 with Data Expected in 2021